التفاصيل البيبلوغرافية
| العنوان: |
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study |
| المؤلفون: |
Löwenberg, Bob, Beck, Joachim, Graux, Carlos, van Putten, Wim, Schouten, Harry C., Verdonck, Leo F., Ferrant, Augustin, Sonneveld, Pieter, Jongen-Lavrencic, Mojca, von Lilienfeld-Toal, Marie, Biemond, Bart J., Vellenga, Edo, Breems, Dimitri, de Muijnck, Hilde, Schaafsma, Ron, Verhoef, Gregor, Döhner, Hartmut, Gratwohl, Alois, Pabst, Thomas, Ossenkoppele, Gert J., Maertens, Johan, for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), German Austrian AML Study Group (AMLSG), Swiss Group for Clinical Cancer Research Collaborative Group (SAKK) |
| المصدر: |
In Blood 1 April 2010 115(13):2586-2591 |
| قاعدة البيانات: |
ScienceDirect |
